Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 8/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.54 |
| ▸ | PLA2G5 | P39877 | 8/20 | 0.54 |
| ▸ | GCGR | P47871 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655398 | 0.88 | PLA2G2A (0.58) | PLA2G10PLA2G2APLA2G5GCGRPPARG | |
| SCHEMBL2643376 | 0.81 | GCGR (0.43) | PLA2G10PLA2G2APLA2G5GCGRELANE | |
| SCHEMBL3573071 | 0.78 | PLA2G10 (0.48) | PLA2G10PLA2G2APLA2G5GCGRPPARG | |
| SCHEMBL15670291 | 0.76 | L3MBTL1 (0.56) | ELANETP53MAPT | |
| SCHEMBL4924224 | 0.74 | PLA2G10 (0.49) | PLA2G10PLA2G2APLA2G5ELANEPPARG | |
| SCHEMBL4920933 | 0.73 | PTGES (0.48) | TP53MAPTTHRB | |
| SCHEMBL2643736 | 0.73 | GCGR (0.51) | PLA2G10GCGRPPARGNOTUMMAPT | |
| Ethoxycarbonyl Group SCHEMBL27678499 | 0.72 | PLA2G10 (0.41) | PLA2G10PLA2G2APLA2G5ELANEPPARG | |
| SCHEMBL3009731 | 0.71 | PTGES (0.52) | GCGRPPARGSCN9ATP53MAPT | |
| SCHEMBL3143440 | 0.71 | NTRK1 (0.48) | ELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | IDO1, IDO2, NPY5R | PLA2G10 3074/4885PLA2G2A 2162/4885PLA2G5 722/4885 |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885PLA2G2A 2484/4885PLA2G5 773/4885 |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885PLA2G2A 2484/4885PLA2G5 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.